Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules

Journal of Urology

Volumn 191, Issue 3, 2014, Pages 611-618

  Atkinson, Bradley J ^a   Kalra, Sarathi ^a   Wang, Xuemei ^a   Bathala, Tharakeswara ^a   Corn, Paul ^a   Tannir, Nizar M ^a   Jonasch, Eric ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

carcinoma; drug administration schedule; drug related side effects and adverse reactions; kidney; renal cell; sunitinib

Indexed keywords

CARCINOMA; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; KIDNEY; RENAL CELL; SUNITINIB;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84893831040     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.08.090     Document Type: Article

References (23)

1. Sutent® (sunitinib) package insert 2012 Pfizer New York
2. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115
3. B.E. Houk, C.L. Bello, and B. Poland et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 66 2010 357
4. S. Faivre, C. Delbaldo, and K. Vera et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 2006 25
5. B. Escudier, J. Roigas, and S. Gillessen et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068
6. C.H. Barrios, D. Hernandez-Barajas, and M.P. Brown et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma Cancer 118 2012 1252
7. R.J. Motzer, T.E. Hutson, and M.R. Olsen et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma J Clin Oncol 30 2012 1371
8. Common Terminology Criteria for Adverse Events (CTCAE) 2009 United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute Bethesda
9. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228
10. D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794
11. B. Escudier, T. Eisen, and W.M. Stadler et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125
12. C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061
13. G. Hudes, M. Carducci, and P. Tomczak et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271
14. B. Escudier, A. Pluzanska, and P. Koralewski et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103
15. B.I. Rini, S. Halabi, and J.E. Rosenberg et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137
16. B. Escudier, C. Szczylik, and T.E. Hutson et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280
17. B.I. Rini, B. Escudier, and P. Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931
18. M.E. Gore, C. Szczylik, and C. Porta et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757
19. B.I. Rini, D.P. Cohen, and D.R. Lu et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763
20. A. Poprach, T. Pavlik, and B. Melichar et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study Ann Oncol 23 2012 3137
21. M. Schmidinger, U.M. Vogl, and M. Bojic et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117 2011 534
22. B. Neri, A. Vannini, and M. Brugia et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients Int J Urol 20 2013 478
23. R.J. Motzer, J. Bacik, and B.A. Murphy et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289